These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18954464)

  • 1. Adjuvant therapy of melanoma with interferon: lessons of the past decade.
    Ascierto PA; Kirkwood JM
    J Transl Med; 2008 Oct; 6():62. PubMed ID: 18954464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline.
    Petrella T; Verma S; Spithoff K; Quirt I; McCready D;
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):413-23. PubMed ID: 22245520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of interferon in melanoma patients: a systematic review.
    Di Trolio R; Simeone E; Di Lorenzo G; Buonerba C; Ascierto PA
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):203-12. PubMed ID: 25511547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
    Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment of malignant melanoma: where are we?
    Ascierto PA; Scala S; Ottaiano A; Simeone E; de Michele I; Palmieri G; Castello G
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):45-52. PubMed ID: 15990330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons in melanoma.
    Agarwala SS; Kirkwood JM
    Curr Opin Oncol; 1996 Mar; 8(2):167-74. PubMed ID: 8727310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
    Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
    Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha for the adjuvant treatment of cutaneous melanoma.
    Mocellin S; Lens MB; Pasquali S; Pilati P; Chiarion Sileni V
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008955. PubMed ID: 23775773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of interferons in the therapy of melanoma.
    Kirkwood JM; Ernstoff MS
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):180S-184S. PubMed ID: 1701805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
    Mozzillo N; Ascierto P
    Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
    Eggermont AM
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):563-9. PubMed ID: 12382524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patients.
    Chapman PB
    J Natl Compr Canc Netw; 2004 Jan; 2(1):69-72. PubMed ID: 19777696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immunologic basis of interferon therapy in melanoma.
    Tarhini AA; Kirkwood JM
    Ann N Y Acad Sci; 2009 Dec; 1182():47-57. PubMed ID: 20074274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
    Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
    Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.